Novartis completes certification of initial sites in Quebec for first approved Canadian CAR-T therapy, Kymriah (tisagenlecleucel)


9 October 2019 - Quebec government to reimburse Kymriah therapy for certain patients with life-threatening cancers who are in critical need

Novartis Pharmaceuticals Canada Inc. is pleased to announce that sites in Quebec have been certified in accordance with applicable requirements to treat eligible patients with Kymriah (tisagenlecleucel), the first chimeric antigen receptor T cell (CAR-T) therapy that received regulatory approval in Canada. Patients with relapsed/refractory (r/r) paediatric and young adult B-cell acute lymphoblastic leukaemia and adult r/r diffuse large B-cell lymphoma may be eligible to be treated with Kymriah at one of the initially certified Canadian treatment sites. 

This news coincides with the Quebec government announcement that Kymriah is now reimbursed for eligible patients under the Régie de l'assurance maladie du Québec (RAMQ).

Read Novartis press release

Michael Wonder

Posted by:

Michael Wonder